● Recruiting

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

Condition: Systemic Lupus Erythematosus · Autoimmune Hemolytic Anemia (AIHA) · Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd.

PhaseEARLY_Phase 1

Planned participants5

Who can joinAll sexes, 18 Years to 60 Years

Healthy volunteersNo

About this study

This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease

This description comes directly from the study's public registry record.

Talk to the study team

Yajing Zhang, M.D. · +86 10-83605002 · yajing_cart66@126.com

Teresa Yang · +86 13902947747 · muyizi.yang@circunited.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing GoBroad Boren Hospital

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07629596